DEVELOPMENT OF NANO IN SITU GELS OF BEVACIZUMAB FOR THE TREATMENT OF OCULAR ANGIOGENESIS: IN VITRO ASSESSMENT OF ANTI-ANGIOGENESIS ACTIVITY AND MOLECULAR DOCKING ANALYSIS

Objective: The present investigation aims to develop nano in situ gels of bevacizumab and evaluate their safety efficacy. Methods: Nanoparticles were designed using the desolvation double emulsion solvent evaporation technique. hen’s egg test: chorioallantoic membrane (HET-CAM) assay was adopted anti-angiogenesis irritancy potential prepared gel. Computational docking study carried out glide module Schrodinger software. Results: FT-IR showed no interaction between components. drug-loaded nanoparticle particle size range 369±5.3 410±3.5, followed by PDI 0.41±0.1 0.73±0.1, ζ–Potential-13±2.3 to-9±3.4. entrapment efficiency nanoparticles found 72.35±1.4 87.22±1.1, loading 8.81±0.3 12.78±0.7. FE-SEM studies resulted an irregular pattern aggregated particles. spherical shape particles confirmed through HR-TEM study. gel exhibited pH 7.2±0.2 7.3±0.1 a viscosity 325.2±8.7 498.7±5.8 mPa. s. CAM assays revealed activity developed formulation. All different concentrations significant anti-angiogenic effect. outcome molecular well-binding capacity with vascular endothelial growth factor (-7.325) human serum albumin (-5.620) residues. Conclusion: above outcomes improved our perception regarding nano-in bevacizumab. Overall, these findings denoted that implementing current idea therapy ocular angiogenesis might be promising platform for better treatment.